Florencia (she/her)

  • 322 Posts
  • 250 Comments
Joined 2 years ago
cake
Cake day: October 23rd, 2024

help-circle














  • From the website for anybody who needs to know ingredients:

    The active ingredient is estradiol enanthate (400 mg). Inactive ingredients are benzyl alcohol (2% w/w) as a preservative and MCT Oil as the carrier. Does not contain benzyl benzoate.

    Edit: My quick internet search can’t find any studies looking at pharmaceutical use past 28 days. I remember reading a super informative post about benzyl alcohol a long time ago.

    Since you’re talking about using it for longer than 30 days, I’d store it in an air tight container in the dark and toss in oxygen reducing packets to eat up all the oxygen in the container. Benzyl alcohol & estradiol both oxidize anyways.

    Edit 2: @sidalsolgun@lemmy.ca quotes https://pghrt.diy/#S5.SS24

    5.24 How long until a vial expires?

    A sealed vial could last for years without issue if it is stored at stable temperatures away from the light. Concerns with age are primarily carrier oil oxidation assuming that the vial was sterilized as it should be. A punctured vial that has a preservative in it (see Question 6.17) should last at least a year or whatever the life time of the vial is (i.e., how long until you use it all). The “discard after 28 days” listing on vials is simply the minimum requirement for how long manufacturers must guarantee sterility, not the maximum shelf life.



  • Nvm. Per https://transfemscience.org/articles/injectable-e2-meta-analysis/

    Additionally, it was noted in this meta-analysis—based on clinical research in cisgender men with prostate cancer—that only modestly supraphysiological estradiol levels, of no more than approximately 200 to 300 pg/mL, are likely to be needed for strong testosterone suppression in transfeminine people. This has likewise been confirmed with solid clinical data in transfeminine people by Herndon et al. (2023), with 88% of those on injectable estradiol monotherapy having testosterone levels of <50 ng/dL at a median injectable estradiol dose of 4 mg/week and with median estradiol levels of 220 pg/mL. It is the opinion of the present author that Herndon et al. (2023) is a very important and formative study, with clinical implications that go far beyond merely supporting the s.c. use of injectable estradiol. The study represents the first major step in the published literature to correcting the dosing and intervals of injectable estradiol in transgender care guidelines and in transgender health generally. I commend the researchers for their work.